feature name,Position,HXB2,Mut,type,HIVdB comment
40_F,40,E,F,NRTI,"E40F is a non-polymorphic accessory mutation selected by AZT and d4T. It usually occurs in combination with M41L, L210W and T215Y. In this context it is associated with reduced susceptibility to each of the NRTIs."
41_I,41,M,I,Other,M41I is usually an artifact resulting from APOBEC3G-mediated hypermutation.
41_L,41,M,L,NRTI,"M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
44_A,44,E,A,NRTI,E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.
44_D,44,E,D,NRTI,E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.
62_V,62,A,V,NRTI,A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic.
65_N,65,K,N,NRTI,"K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT. K65N is a rare mutation with similar but less pronounced effects on NRTI susceptibility than K65R."
65_R,65,K,R,NRTI,"K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
65_E,65,K,E,NRTI,"K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT. K65E is an extremely rare NRTI-selected mutation with markedly reduced replication fitness."
67_del,67,D,del,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex."
67_N,67,D,N,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
67_H,67,D,H,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
67_G,67,D,G,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
67_E,67,D,E,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
67_S,67,D,S,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
67_T,67,D,T,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
68_del,68,S,del,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex. Deletions at codon 68 are extremely rare and less well characterized."
68_G,68,S,G,Other,S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R.
69_A,69,T,A,Other,T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied.
69_S,69,T,S,Other,T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied.
69_N,69,T,N,Other,"T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
69_E,69,T,E,Other,T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied.
69_I,69,T,I,Other,T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied.
69_ins,69,T,ins,NRTI,"Amino acid insertions between codons 67 and 70 are by convention assigned to codon 69. Together with TAMs, they are associated with high-level resistance to AZT, d4T, ddI, ABC and TDF and intermediate to 3TC and FTC."
69_del,69,T,del,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex."
69_G,69,T,G,NRTI,T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations.
69_D,69,T,D,NRTI,T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T.
70_S,70,K,S,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
70_T,70,K,T,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
70_del,70,K,del,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex."
70_Q,70,K,Q,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
70_N,70,K,N,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
70_E,70,K,E,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
70_R,70,K,R,NRTI,"K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
70_G,70,K,G,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
74_I,74,L,I,NRTI,L74V/I cause high-level resistance to ddI and intermediate resistance to ABC.
74_V,74,L,V,NRTI,L74V/I cause high-level resistance to ddI and intermediate resistance to ABC.
75_T,75,V,T,NRTI,V75T causes high-level d4T resistance and intermediate ddI resistance.
75_I,75,V,I,NRTI,V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.
75_A,75,V,A,NRTI,V75S/A are non-polymorphic mutations that appear to reduce susceptibility to d4T and ddI.
75_S,75,V,S,NRTI,V75S/A are non-polymorphic mutations that appear to reduce susceptibility to d4T and ddI.
75_M,75,V,M,NRTI,"V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
77_L,77,F,L,NRTI,"F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
90_I,90,V,I,Other,"V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
98_G,98,A,G,NNRTI,A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.
100_V,100,L,V,NNRTI,"L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV."
100_I,100,L,I,NNRTI,"L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
101_H,101,K,H,NNRTI,"K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
101_E,101,K,E,NNRTI,"K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
101_Q,101,K,Q,Other,K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance.
101_T,101,K,T,Other,K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.
101_N,101,K,N,Other,K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.
101_A,101,K,A,Other,K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.
101_P,101,K,P,NNRTI,K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.
103_T,103,K,T,NNRTI,K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.
103_S,103,K,S,NNRTI,"K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
103_N,103,K,N,NNRTI,K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.
103_R,103,K,R,Other,"K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
103_Q,103,K,Q,NNRTI,K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility.
103_E,103,K,E,NNRTI,K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility.
103_H,103,K,H,NNRTI,K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.
106_I,106,V,I,NNRTI,"V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs."
106_A,106,V,A,NNRTI,V106A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It is selected in vitro and in vivo by DOR and alone it causes intermediate reductions in DOR susceptibility. In combination with other DOR-associated DRMs it is associated with high-level DOR resistance.
106_M,106,V,M,NNRTI,V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.
108_I,108,V,I,NNRTI,"V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
115_F,115,Y,F,NRTI,Y115F causes intermediate resistance to ABC and low-level resistance to TDF.
116_Y,116,F,Y,NRTI,F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M.
118_I,118,V,I,Other,V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.
132_L,132,I,L,Other,"I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
132_M,132,I,M,Other,"I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
138_G,138,E,G,NNRTI,"E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
138_K,138,E,K,NNRTI,"E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR but no cross-resistance to NVP, EFV, or DOR."
138_Q,138,E,Q,NNRTI,"E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR."
138_A,138,E,A,NNRTI,E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.
138_R,138,E,R,NNRTI,E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV.
151_M,151,Q,M,NRTI,"Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
151_L,151,Q,L,NRTI,"Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M."
179_D,179,V,D,NNRTI,V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.
179_E,179,V,E,NNRTI,V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.
179_F,179,V,F,NNRTI,"V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
179_L,179,V,L,NNRTI,V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.
179_T,179,V,T,NNRTI,"V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
179_I,179,V,I,Other,"V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
181_F,181,Y,F,NNRTI,Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.
181_S,181,Y,S,NNRTI,Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.
181_I,181,Y,I,NNRTI,"Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
181_G,181,Y,G,NNRTI,Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.
181_C,181,Y,C,NNRTI,"Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
181_V,181,Y,V,NNRTI,"Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
184_I,184,M,I,NRTI,"M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
184_V,184,M,V,NRTI,"M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
188_C,188,Y,C,NNRTI,Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV.
188_F,188,Y,F,NNRTI,Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.
188_H,188,Y,H,NNRTI,Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV.
188_L,188,Y,L,NNRTI,"Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
190_R,190,G,R,Other,G190R is strongly suspicious for being an artifact of APOBEC-mediated G-to-A hypermutation. It has not been associated with reduced NNRTI susceptibility.
190_V,190,G,V,NNRTI,"G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
190_A,190,G,A,NNRTI,G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.
190_C,190,G,C,NNRTI,"G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
190_T,190,G,T,NNRTI,"G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
190_S,190,G,S,NNRTI,G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.
190_Q,190,G,Q,NNRTI,"G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
190_E,190,G,E,NNRTI,"G190E is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs including DOR. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
210_W,210,L,W,NRTI,"L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
215_I,215,T,I,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_D,215,T,D,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_E,215,T,E,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_F,215,T,F,NRTI,"T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
215_A,215,T,A,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_L,215,T,L,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_Y,215,T,Y,NRTI,"T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
215_S,215,T,S,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_V,215,T,V,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_N,215,T,N,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
215_C,215,T,C,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
219_N,219,K,N,NRTI,K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs.
219_Q,219,K,Q,NRTI,K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T.
219_R,219,K,R,NRTI,K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs.
219_E,219,K,E,NRTI,K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T.
219_W,219,K,W,NRTI,K219W is an uncommon NRTI-selected mutation.
221_Y,221,H,Y,NNRTI,H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.
225_H,225,P,H,NNRTI,"P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
227_I,227,F,I,NNRTI,F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.
227_V,227,F,V,NNRTI,F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.
227_L,227,F,L,NNRTI,F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.
227_C,227,F,C,NNRTI,"F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or higher reductions in susceptibility to NVP, EFV, ETR, and RPV."
230_I,230,M,I,NNRTI,M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious.
230_L,230,M,L,NNRTI,"M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
234_I,234,L,I,NNRTI,"L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been studied."
236_L,236,P,L,NNRTI,P236L is a non-polymorphic mutation that causes high-level DLV resistance but does not reduce susceptibility to any other NNRTIs.
238_T,238,K,T,NNRTI,"K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
238_N,238,K,N,NNRTI,"K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
238_R,238,K,R,Other,K238R is a common polymorphism that does not reduce NNRTI susceptibility.
318_F,318,Y,F,NNRTI,Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR but its effect on DOR susceptibility has not been studied.
348_I,348,N,I,NNRTI,N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.